Ads

You May Also Like

Interface Biologics Announces New V.P., Business Development

TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Interface Biologics Inc. (“IBI”), a privately held, ...

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including ...

Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results

MEDFORD, N.Y., March 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leader ...